6-(Difluoromethoxy)-2,4-dimethyl-3-pyridinamine | 1224432-57-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(Difluoromethoxy)-2,4-dimethyl-3-pyridinamine
• 英文别名: 6-(difluoromethoxy)-2,4-dimethylpyridin-3-amine
• CAS: 1224432-57-8
• 化学式: C₈H₁₀F₂N₂O
• 分子量: 188.177
• InChiKey: NIXJRPSQAPJJBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-3,5-dichloro-1-(1-cyclopropyl-2-methoxyethyl)pyrazin-2(1H)-one 、 6-(Difluoromethoxy)-2,4-dimethyl-3-pyridinamine 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 生成 (S)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(6-(difluoromethoxy)-2,4-dimethylpyridin-3-ylamino)pyrazin-2(1H)-one
  参考文献：
  名称：

  Synthesis and structure–activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists

  摘要：

  A series of N-3-pyridylpyrazinones was investigated as corticotropin-releasing factor-1 receptor antagonists. It was observed that the binding affinity of analogues containing a pyridyl group was influenced not only by the substitution pattern on the pyridyl group, but also by the pK(a) of the pyridyl nitrogen. Analogues containing a novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group were among the most potent N-3-pyridylpyrazinones synthesized. The synthesis and SAR of N-3-pyridylpyrazinones is described herein. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.129
• 作为产物：
  描述：

  6-(Difluoromethoxy)-2,4-dimethyl-3-nitropyridine 在 1% Pd/C 、 氢气 作用下， 以 乙醇 为溶剂， 以88%的产率得到6-(Difluoromethoxy)-2,4-dimethyl-3-pyridinamine
  参考文献：
  名称：

  Synthesis and structure–activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists

  摘要：

  A series of N-3-pyridylpyrazinones was investigated as corticotropin-releasing factor-1 receptor antagonists. It was observed that the binding affinity of analogues containing a pyridyl group was influenced not only by the substitution pattern on the pyridyl group, but also by the pK(a) of the pyridyl nitrogen. Analogues containing a novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group were among the most potent N-3-pyridylpyrazinones synthesized. The synthesis and SAR of N-3-pyridylpyrazinones is described herein. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.129

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243535A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及式(I)的O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这种化合物的药物组合物，用于制备这种化合物和组合物的方法，以及利用这种化合物和组合物预防和治疗OGA抑制对其有益的疾病的应用，特别是τ蛋白病，如阿尔茨海默病或进行性核上性麻痹症；以及伴有τ病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化和颞叶前叶痴呆症。
• OGA INHIBITOR COMPOUNDS
  申请人：Janssen Pharmaceutica NV

  公开号：US20210130352A1

  公开（公告）日：2021-05-06

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.